Session XXII: Colorectal Cancer: Metastatic Disease
Presentation during WCGIC:
All abstracts will be published on the Annals of Oncology website on Saturday, 02 July at 16:30 CEST.
Abstract titles and summaries were obtained from the ESMO WCGIC website; abstracts were translated, edited, and summarized in German.
------------------------------------------------------------------------------------------------------------------------------------------
O-6: Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients:
results of the phase III randomized TRIPLETE study by GONO
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
O-7: Evidence of therapeutic effectiveness of III line cetuximab rechallenge in appropriately selected patients: finding from long-term follow-up of CRICKET and CAVE trials
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
SO-37: Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib:
subanalysis of BEACON CRC
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
SO-38: Clinical efficacy and single cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
O-8: Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
LBA-2: MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------
SO-39: Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
Summary in German follows soon on Saturday, July 2, 2022, after 11AM
------------------------------------------------------------------------------------------------------------------------------------------